Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05DNW
|
||||
| Drug Name |
B-623
|
||||
| Synonyms |
149732-37-6; B-623
|
||||
| Indication | Unspecified | Investigative | [1560234] | ||
| Target and Pathway | |||||
| Target(s) | Urokinase-type plasminogen activator | Target Info | Modulator | ||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| E2F transcription factor network | |||||
| Beta3 integrin cell surface interactions | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| Beta2 integrin cell surface interactions | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| FGF signaling pathway | |||||
| Reactome | Dissolution of Fibrin Clot | ||||
| References | |||||